Begin main content

Appropriate Pharmacotherapy for Inflammatory Bowel Disease

Last updated: February 11, 2019
Project Number: HE0018-000
Product Line: Technology Review
Result type: Report
Expected Completion Date: June 27, 2019

In 2018, around 270,000 Canadians were living with inflammatory bowel disease (IBD), which comprises Crohn’s disease and ulcerative colitis. Several drug classes, including corticosteroids, immunomodulators and anti-inflammatory biologics, can induce and maintain remission of IBD. CADTH is undertaking a series of reviews of the clinical and economic evidence surrounding drugs for IBD to clarify their relative place in therapy and inform appropriate reimbursement criteria by public drug plans.

Projects listed as “in progress” are at various stages and points of completion. These products have different processes and timelines; therefore, the timing of posting of the final reports varies and expected completion dates may change. Find out more about Projects in Progress.

The “Projects in Progress” page on the CADTH website is updated on a seven- to eight-day cycle. Please be advised that there may be overlap between when a new report is posted online and when the section is updated. View our current Projects in Progress.